| 2016 updated EULAR evidence-based recommendations for the management of gout P Richette, M Doherty, E Pascual, V Barskova, F Becce, ... Annals of the rheumatic diseases 76 (1), 29-42, 2017 | 1697 | 2017 |
| 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative T Neogi, TLTA Jansen, N Dalbeth, J Fransen, HR Schumacher, ... Arthritis & rheumatology 67 (10), 2557-2568, 2015 | 1408 | 2015 |
| European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis W Zhang, M Doherty, T Bardin, V Barskova, PA Guerne, TL Jansen, ... Annals of the rheumatic diseases 70 (4), 563-570, 2011 | 602 | 2011 |
| Gout: why is this curable disease so seldom cured? M Doherty, TL Jansen, G Nuki, E Pascual, F Perez-Ruiz, L Punzi, AK So, ... Annals of the rheumatic diseases 71 (11), 1765-1770, 2012 | 353 | 2012 |
| 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout P Richette, M Doherty, E Pascual, V Barskova, F Becce, J Castaneda, ... Annals of the rheumatic diseases 79 (1), 31-38, 2020 | 335 | 2020 |
| EULAR recommendations for calcium pyrophosphate deposition. Part II: management W Zhang, M Doherty, E Pascual, V Barskova, PA Guerne, TL Jansen, ... Annals of the rheumatic diseases 70 (4), 571-575, 2011 | 297 | 2011 |
| Improving cardiovascular and renal outcomes in gout: what should we target? P Richette, F Perez-Ruiz, M Doherty, TL Jansen, G Nuki, E Pascual, ... Nature Reviews Rheumatology 10 (11), 654-661, 2014 | 258 | 2014 |
| Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study S Arends, E Brouwer, E van der Veer, H Groen, MK Leijsma, PM Houtman, ... Arthritis research & therapy 13, 1-10, 2011 | 253 | 2011 |
| Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra TO Crișan, MCP Cleophas, M Oosting, H Lemmers, H Toenhake-Dijkstra, ... Annals of the rheumatic diseases 75 (4), 755-762, 2016 | 246 | 2016 |
| A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout MK Reinders, C Haagsma, TLTA Jansen, EN Van Roon, J Delsing, ... Annals of the Rheumatic Diseases 68 (6), 892-897, 2009 | 245 | 2009 |
| The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice W Kievit, J Fransen, AJM Oerlemans, HH Kuper, M Van Der Laar, ... Annals of the rheumatic diseases 66 (11), 1473-1478, 2007 | 217 | 2007 |
| International consensus definition of low anterior resection syndrome C Keane, NS Fearnhead, L Bordeianou, P Christensen, E Espin Basany, ... Colorectal Disease 22 (3), 331-341, 2020 | 202 | 2020 |
| Imaging modalities for the classification of gout: systematic literature review and meta-analysis A Ogdie, WJ Taylor, M Weatherall, J Fransen, TL Jansen, T Neogi, ... Annals of the rheumatic diseases 74 (10), 1868-1874, 2015 | 202 | 2015 |
| Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol MK Reinders, EN Van Roon, TLTA Jansen, J Delsing, EN Griep, ... Annals of the rheumatic diseases 68 (1), 51-56, 2009 | 201 | 2009 |
| Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating … JP Cremers, M Drent, A Bast, H Shigemitsu, RP Baughman, D Valeyre, ... Current Opinion in Pulmonary Medicine 19 (5), 545-561, 2013 | 200 | 2013 |
| Early extracorporeal CPR for refractory out-of-hospital cardiac arrest MM Suverein, TSR Delnoij, R Lorusso, GJ Brandon Bravo Bruinsma, ... New England Journal of Medicine 388 (4), 299-309, 2023 | 177 | 2023 |
| Gout—current diagnosis and treatment AK Tausche, TL Jansen, HE Schröder, SR Bornstein, M Aringer, ... Deutsches Ärzteblatt International 106 (34-35), 549, 2009 | 167 | 2009 |
| The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data W Kievit, EM Adang, J Fransen, HH Kuper, M Van De Laar, TL Jansen, ... Annals of the rheumatic diseases 67 (9), 1229-1234, 2008 | 158 | 2008 |
| Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial V Klück, L Tim, M Janssen, A Comarniceanu, M Efdé, IW Tengesdal, ... The Lancet Rheumatology 2 (5), e270-e280, 2020 | 152 | 2020 |
| Study for updated gout classification criteria: identification of features to classify gout WJ Taylor, J Fransen, TL Jansen, N Dalbeth, HR Schumacher, M Brown, ... Arthritis care & research 67 (9), 1304-1315, 2015 | 150 | 2015 |
P.L.C.M. van Rielemeritus hoogleraar reumatologie nijmegenVerified email at radboudumc.nl
